Our Next Show: Predicting Treatment Response in Multiple Myeloma, Friday, June 12 @ 10 am CST
Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer Could doctors predict how you might respond to standard myeloma therapies based on the genetics of your myeloma? Dr. Brian Van Ness is now leading a study at the University of Minnestoa in collaboration with the Mayo Clinic to determine just that. His study matching up myeloma genomics with proteasome inhibitors will help to segment myeloma patients into groups to learn when and where they work - and where they don't. Learn about his work to personalize myeloma therapy, reduce toxicity and eliminate unnecessary (and non-working) therapies from the mix based on your unique kind of myeloma. Dr. Brian Van Ness, Ph.D., is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota Medical School. He served as the Head of the Department for nine years, then served as a Director of the Institute of Human Genetics and Director of a newly established Division of Medical Genomics. After receiving a bachelor’s degree in biology and a master’s degree in chemistry from the Indiana University of Pennsylvania in Indiana, PA, Dr. Van Ness obtained his Ph.D. in biochemistry from the University of Minnesota. He conducted his postdoctoral work in molecular immunology with the Institute for Cancer Research in Fox Chase, PA. His current research focuses on exploring how genetic variations influence disease progression and therapeutic response, particularly with regard to cancer. He has published over 150 papers on his research studies. He is Founder and CEO of a new company, Target Genomics, LLC (www.targetgenomics.com), that focuses on guiding healthcare providers on the use of genomics. This centers on PRIMROSE, a searchable resource for identifying and implementing clinical applications of genetics in drug therapies. He was a Senior Fellow of Commercialization at Minneapolis based Life Science Alley and the BioBusiness Alliance, and served on the Advisory Board for Alley Institute. He has been active in regulatory and legal issues in genomics, both as expert consultant in patent litigation, as well as a member of an NIH supported committee, making recommendations on return of genetic results. Dr. Van Ness has recently created a joint course with the Law School, “Genetics and Law.” In addition to teaching responsibilities in the Medical and Law curriculum, Dr. Van Ness is a frequent guest speaker for continuing medical education programs and patient support groups around the country on genomics and personalized medicine. Special thanks to our program sponsor, Takeda Oncology.